Journey Clinical, a New York-based company focused on providing psychedelic therapies, raised $8.5M in Series A funding.
The round, which brings Journey Clinical’s total funding to ~$12M, was led by Union Square Ventures with participation from AlleyCorp, Fifty Years, Able Partners, Gaingels, Palo Santo, PsyMed Ventures, Coalition Operators, Mystic Ventures, Colibri, Satori Capital, and other angel investors.
The company intends to use the funds to continue to scale its offerings across the US.
Co-founded by Jonathan Sabbagh (CEO) and Myriam Barthes (COO), Journey Clinical provides both licensed psychotherapists and patients with access to psychedelic therapies. Licensed psychotherapists receive everything they need to confidently deliver PAP within their own practice, while eligible patients gain access to its medical team for evaluation and care, and network of licensed mental health professionals. The company started with Ketamine-Assisted Psychotherapy (KAP) and will expand to other psychotherapeutic treatments in the future as they continue to be validated, researched, and approved for broad use by the FDA.
Since the company opened the platform in February 2022, they have grown from 30 to ~700 KAP psychotherapists, and have treated over 1,000 patients across the country.